The health and economic benefits of the global programme to eliminate lymphatic filariasis (2000–2014)

Table 8 Summary of the benefit cohorts

Benefit cohort	Population size (millions)	Average age at MDA treatment	Average years of health and economic benefit^a	Person-years (millions)^b
1. Protected from acquiring infection	21	20	45.6	938
2. Subclinical morbidity prevented from progressing	12.5	20	45.6	551
3. Alleviated clinical disease	12.8	30	35.6	450^c
Total	46	-	-	1,939

^aBased on a global weighted average life expectancy of 64.6 years (weighted based on the benefit cohort population size in each endemic country)
^bThe sum of the number of years lived by each individual in the benefit cohort population. (Equal to the benefit cohort population multiplied by the average years of health and economic benefit (after adjusting for mortality))
^cIncludes both those with alleviated chronic disease and these with reduced frequency of ADL episodes (Fig. 3)

ISSN: 2049-9957